USFDA inspection at Alembic Pharmaceuticals Injectable Facility (F-3) at Karkhadi

Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke

Biological E. announces CDSCO recommendation of its infant’s vaccine

Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)

Merck India inaugurates R&D Excellence Centre in Bangalore

The Centre aims at promoting innovation among the scientific community to improve healthcare solutions around the globe

Zydus announces Phase IV DREAM-CKD trial of Desidustat in patients with CDK induced anemia

The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.

Thermo Fisher Scientific present new innovations to improve biopharmaceutical and proteomics workflows

New mass spectrometry instrument and consumables launch during IMSC 2022

Dr. Mansukh Mandaviya and Bhagwanth Khuba to grace Silver Jubilee function of NPPA

To mark the occasion, Integrated Pharmaceutical Database Management System 2.0 (IPDMS 2.0), an integrated responsive cloud-based application developed by NPPA with technical support from C-DAC will be launched

USFDA completes inspection at Aurolife Pharma’s Raleigh unit

The unit has filed 2 Derma products and 1 MDI product.

Cipla receives 6 observations from USFDA for Goa facility

There are no data integrity (DI) observations.

Moderna files for emergency use of BA.4/BA.5 Omicron booster

Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September